145 patients of DCM cohort with LV ejection fraction < 35% were divided into 3 groups. Group 1 with normal LV dimensions, group 2 with mild-moderately enlarged left ventricle and group 3 with severely dilated left ventricle. Primary endpoint was composite of all cause mortality and heart failure hospitalizations at end of follow-up.
Forty-four patients (30.3%) with normal LV diastolic diameter (51.9 ± 5.3 mm) were included in group 1, 57(39.3%) with mild-moderately enlarged LV (61.4 ± 3.7 mm) in group 2 and 44(30.3%) with severely enlarged LV (71.3 ± 7.4 mm) in group 3. Mean follow-up was 42.2 ± 31.6 months. Primary end point occurred in 4 patients (9.1%) in group 1, 8 patients (14%) in group 2 and 9 patients (20.5%) in group 3, p = 0.23 by log-rank test. Hazard ratio for primary endpoint in group 2 as compared to group 1 was 1.71(95% CI, 0.51 to 5.67; p = 0.39) and in group 3 as compared to group 1 was 1.61(95% CI, 0.89 to 2.91; p = 0.11). Of patients with more than two years of follow-up, 2 of 29 patients(6.9%) died in group 1, 3 of 35 patients(8.6%) in group 2 and 3 of 34 patients(8.8%) died in group 3, p = 0.95.
Intermediate term prognosis of patients with severe LVSD and severely dilated left ventricle is good, with outcomes similar to patients with normal or mild-moderately dilated left ventricle.